PDCT-03. A Phase Ii Trial of Poly-Iclc in the Management of Recurrent or Progressive Pediatric Low Grade Gliomas. Results for the Neurofibromatosis 1 Group. (Nct01188096)

Aguilera, Dolly; MacDonald, Tobey J.; Castellino, Robert C.; Janss, Anna J.; Mazewski, Claire; Kadom, Nadja; Pu, Minya; Messer, Karen; Crawford, John R.; Connelly, Erin; Gray, Rachel; Salazar, Andrés M.; Durden, Donald L.

doi:10.1093/neuonc/noy148.833

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, one Phase I study evaluated the therapeutic effect of TLR3 agonists in pediatric cancers (NCT01188096). 192 Of note, all six patients affected by type I neurofibromatosis (among the 23 enrolled in the trial) tolerated Hiltonol™ as a stand-alone intervention (mild side effects included fever, pain at site of injection, erythema and myalgias), 192 supporting the planification of a Phase II study for this specific oncological indication.…”

Section: Clinical Studiesmentioning

confidence: 94%

“…Since the submission of the latest Trial Watch dealing with this topic (October 2018), 90 only 8 clinical studies encompassing the administration of TLR3 agonists to cancer patients have been initiated (source http://clinicaltrials.gov/ ), all of which involved either Hiltonol™ (4 studies), 193 – 195 or Ampligen™ (4 studies) 151 ( Table 1 ).…”

Section: Recently Initiated Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Trial watch: TLR3 agonists in cancer therapy

et al. 2020

View full text Add to dashboard Cite

Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion of pro-inflammatory cytokines including type I interferon (IFN). The latter is essential not only for innate immune responses to infection but also for the initiation of antigen-specific immunity against viruses and malignant cells. These aspects of TLR3 biology have supported the development of various agonists for use as stand-alone agents or combined with other therapeutic modalities in cancer patients. Here, we review recent preclinical and clinical advances in the development of TLR3 agonists for oncological disorders.

show abstract

Section: Clinical Studiesmentioning

confidence: 94%